[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"serous-tubal-intraepithelial-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:serous-tubal-intraepithelial-carcinoma":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,74,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":56,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100474891","inadvance-surveillance-prevention-and-interception-in-a-population-at-risk-for-cancer-100474891",false,"NCT05463796","InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer","Inclusion Criteria:\n\n* Participants to be included in this study include the following (note that this list is not comprehensive but gives examples of precursor conditions for each organ type):\n\n  1-Hereditary risk for cancer including\n  * Carriers of known or previously unrecognized pathogenic germline variants of cancer predisposing genes\n  * Individuals with personal or family history suggestive of elevated cancer risk (this may include individuals who have negative genetic testing results or have not elected to undergo testing)\n  * Individuals with a clinically based diagnosis of a Cancer Predisposition Syndrome (examples, neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia)\n  * Hereditary Cancer Prediction Model-based elevated cancer risk\n  * Others at risk for specific cancers by virtue of exposure, obesity, gender, race and ethnicity, HPV exposure (for H\\&N cancer for example), etc.\n* Exposed High Risk including\n\n  * Childhood cancer survivors with treatment exposures associated with increased risk of cancer\n  * Adult cancer survivors with treatment exposures associated with increased risk of cancer\n  * Documented high level exposure to group 1 IARC carcinogens\n  * Thoracic: individuals at risk for lung cancer including but not exclusive of the following criteria: Age \\>50, Smoking history of \\>15 pack years, First-degree relative history of lung cancer or COPD\n  * alcoholic liver disease (NAFL), non-alcoholic steatohepatitis (NASH), cirrhosis\n* Precursor Lesions including\n\n  * Breast: ductal\u002Flobular carcinoma in situ (CIS) and atypical hyperplasia\n  * GI: Barrett's esophagus, Pancreatic precursor lesions, colonic dysplasia\u002Fadenomata, nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), cirrhosis\n  * GU: High grade prostatic epithelial neoplasia, and high-grade bladder urothelial dysplasia\u002Fcarcinoma in situ,\n  * Lung: Adenomatous hyperplasia\n  * H\\&N: high-risk oral precancerous diseases\n  * Skin: Class II melanocytic lesions. Squamous dysplasia\n  * Heme malignancies: CHIP, CCUS, ICUS, MGUS, SMM, SWM, MBL (spell these out), Low grade lymphomas\n  * Thoracic: Lung nodules detected on screening CT that prompt further follow-up\n  * GYN: STIC lesion (serous tubal intraepithelial carcinoma), Endometrial intraepithelial neoplasia, Cervical and endocervical carcinoma in situ, vulvar intraepithelial neoplasia\n  * Pediatric histologic diagnoses sometimes associated with development of malignancy: Nephrogenic rests, benign bone lesions with risk of malignant degeneration (Giant cell tumor, osteochondroma), Spitz nevus, and others.\n* FAMILY MEMBERS or healthy individuals\n\nExclusion Criteria:\n\nThere are no exclusion criteria for the study.\n\nNote: Patients with prior cancer history are allowed to participate. Patients with prior history of cancer or non-metastatic localized cancers (such as skin cancer or localized prostate cancer) are allowed to be enrolled. Patients enrolled in clinical trials or receiving therapy for precursor diseases are NOT excluded from this study.",true,"ALL",{"count":19,"type":20},5000,"ESTIMATED","20 Years","OBSERVATIONAL","This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer.\n\n* The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal.\n* The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55],"Cancer Risk","Cancer Predisposition Syndrome","Hereditary Cancer Prediction","Childhood Cancer Survivors","Adult Cancer Survivors","IARC Carcinogens","Smoking History","Lung Cancer","Ductal\u002FLobular Carcinoma","Barrett Esophagus","Pancreatic Precursor Lesions","Colonic Dysplasia\u002FAdenomata","Non-Alcoholic Fatty Liver Disease","Non Alcoholic Steatohepatitis","Cirrhosis","High Grade Prostatic Epithelial Neoplasia","High-grade Bladder Urothelial Dysplasia\u002FCarcinoma in Situ","Adenomatous Hyperplasia","High-risk Oral Precancerous Diseases","Melanocytic Lesion, Adult","Hematologic Malignancy","Lung; Node","Serous Tubal Intraepithelial Carcinoma","Endometrial Intraepithelial Neoplasia","Cervical and Endocervical Carcinoma in Situ","Vulvar Intraepithelial Neoplasia","Nephrogenic Rests","Benign Bone Lesions With Risk of Malignant Degeneration","Giant Cell Tumor","Osteochondroma","Spitz Nevus",[57,58,59,60],"Hereditary Risk for Cancer","Childhood cancer survivors","Adult cancer survivors","Precursor Lesions","RECRUITING","2026-08-13",{"date":64,"type":65},"2026-08-17","ACTUAL",{"date":67,"type":65},"2023-04-25",{"date":69,"type":20},"2031-03-25",{"name":71,"class":72},"Dana-Farber Cancer Institute","OTHER",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":82,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":95,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100651725","ovarian-cancer-liquid-biopsy-for-early-assessment--detection-in-individuals-with-brca12-pathogenic-variants-100651725","NCT07764744","Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1\u002F2 Pathogenic Variants","Ovarian Cancer Liquid Biopsy for Early Assessment & Detection (OC-LEAD)","OC-LEAD","Inclusion Criteria:\n\nCohort A participants must meet all of the following criteria:\n\n1. Age ≥ 35 years (based on current National Comprehensive Cancer Network guidelines35 for risk-reducing gynecologic surgery) with no upper age limit\n2. Confirmed germline PV or likely PV in the BRCA1 or BRCA2 genes, documented by CLIA-certified genetic testing.\n3. Scheduled to undergo risk-reducing gynecologic surgery (salpingo-oophorectomy or salpingectomy with or without hysterectomy) at the study site.\n4. Willing and able to provide informed consent in English This initial phase is limited to English-speaking participants. This limitation is due to feasibility considerations for initial qualitative instrument validation; future phases will incorporate translated materials\n\n   Cohort B participants must meet all of the following criteria:\n5. Age ≥ 35 years with no upper age limit.\n6. STIC lesion previously identified on surgical pathology within the prior 10 years.\n7. Willing and able to undergo baseline and annual research blood draws for up to 10 years following STIC lesion diagnosis.\n8. Willing and able to provide informed consent in English\n\nExclusion Criteria:\n\nCohort A:\n\n1. Pregnant or breastfeeding at the time of enrollment.\n2. Prior removal of bilateral fallopian tubes and\u002For bilateral ovaries.\n3. Active diagnosis of cancer.\n4. Prior or active diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer at the time of consent.\n5. Patients with a history of cancer are eligible when \\> 2 years no evidence of disease.\n6. Inability to provide informed consent.\n7. Concurrent participation in another interventional trial that may confound study outcomes.\n\nCohort B:\n\n1. Pregnant or breastfeeding at the time of enrollment.\n2. Active diagnosis of cancer.\n3. Prior or active diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer at the time of consent (prior STIC lesion is NOT a contraindication to enrollment).\n4. Patients with a history of cancer are eligible when \\> 2 years no evidence of disease.\n5. Inability to provide informed consent.\n6. Concurrent participation in another interventional trial that may confound study outcomes.","FEMALE","35 Years",{"count":85,"type":20},70,"INTERVENTIONAL",[88],"NA","The goal of this clinical study is to evaluate the feasibility and acceptability of the Galleri multi-cancer early detection blood test in people with BRCA1 or BRCA2 gene changes who are at high risk for ovarian cancer. The study will also explore how well the test detects ovarian cancer or related precancerous conditions.\n\nThe main questions it aims to answer are:\n\n* Is it feasible to incorporate the Galleri blood test into the care of people at high \\* risk for ovarian cancer?\n* Is the Galleri blood test acceptable to participants?\n* How well does the Galleri blood test identify ovarian cancer or related precancerous conditions?\n\nParticipants will:\n\n* Receive the Galleri blood test.\n* Complete questionnaires about their experience with the test.\n* Some participants will also complete an interview about their experiences and preferences.\n* Continue with their planned standard medical care, including surgery or follow-up visits, as appropriate.",[91,92,93,47,94],"Ovarian Neoplasms","BRCA 1 Gene Mutation","BRCA 2 Gene Mutation","Early Detection of Ovarian Cancer",[96,97,98,99,100,101,102,103,104,105,106,107,108],"Ovarian cancer","Liquid biopsy","Galleri","Multi-cancer early detection","BRCA1","BRCA2","Hereditary breast and ovarian cancer syndrome","Serous tubal intraepithelial carcinoma (STIC)","Risk-reducing salpingo-oophorectomy","Early cancer detection","Hereditary cancer","Cancer screening","Implementation science","NOT_YET_RECRUITING","2026-08-10",{"date":112,"type":65},"2026-08-14",{"date":114,"type":20},"2026-08",{"date":116,"type":20},"2039-07",{"name":118,"class":72},"Weill Medical College of Cornell University",2,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":82,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":131,"studyType":22,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":4},"100546331","international-registration-of-isolated-stic-to-report-and-investigate-the-risk-of-serous-peritoneal-carcinomatosis-100546331","NCT06393543","International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis","STICRISC","Inclusion Criteria:\n\n* Women\n* Bilateral salpingectomy (with or without oophorectomy)\n* A serous tubal intraepithelial carcinoma at histopathological review\n\nExclusion Criteria:\n\n* Invasive cancer at initial surgery or pathological examination (either macroscopic and\u002For microscopic)","18 Years","100 Years",{"count":130,"type":20},600,"10 Years","To prospectively assess the incidence of peritoneal carcinomatosis for women with isolated STIC (serous tubal intraepithelial carcinoma). Moreover, to identify histopathological characteristics of STIC which are reproducible and associated to the risk of peritoneal carcinomatosis and to report the findings of additional diagnostics.",[134,47,135,136],"BRCA Mutation","Ovarian Carcinoma","Peritoneal Carcinoma","2024-04-26",{"date":139,"type":65},"2024-05-01",{"date":141,"type":20},"2024-06",{"date":143,"type":20},"2034-06",{"name":145,"class":72},"Radboud University Medical Center"]